Attention-deficit/hyperactivity disorder medication and risk of suicide attempt: A meta-analysis of observational studies.
ADHD
children
pharmacoepidemiology
suicidal behavior
suicide
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
02
03
2020
revised:
03
08
2020
accepted:
11
08
2020
pubmed:
3
9
2020
medline:
28
10
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
Epidemiologic findings are inconsistent regarding the association between attention-deficit/hyperactivity disorder (ADHD) medication exposure and suicide attempt in individuals with ADHD. A systematic literature search of PubMed, Embase and Cochrane Library up to February 2020 was performed. A meta-analysis was conducted for outcomes in which a summary risk ratio (RR) was calculated when taking heterogeneity into account. Both population-level and within-individual analyzes showed that ADHD medication was associated with lower odds of suicide attempts (RR = 0.76, 95% confidence interval [CI], 0.58-1.00; P = .049 and RR = 0.69; 95% CI, 0.49-0.97; P = .049, respectively). However, the association only existed for participants who were treated with stimulants (RR = 0.72; 95% CI, 0.53-0.99; P = .042 on population-level analysis and RR = 0.75; 95% CI, 0.66-0.84; P < .001 on within-individual analysis). Furthermore, a lower risk of suicide attempts was not observed in subjects who took ADHD medication for 1 to 90 days (RR = 0.91; 95% CI, 0.74-1.13; P = .416 on within-individual analysis). The results indicate that non-stimulant treatment is not associated with a higher risk of suicide attempt, but stimulant treatment is associated with a lower risk of suicide attempt.
Substances chimiques
Central Nervous System Stimulants
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1364-1372Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Turecki G, Brent DA. Suicide and suicidal behaviour. Lancet (London, England). 2016;387(10024):1227-1239.
Bould H, Mars B, Moran P, Biddle L, Gunnell D. Rising suicide rates among adolescents in England and Wales. Lancet (London, England). 2019;394(10193):116-117.
Stone DM, Simon TR, Fowler KA, et al. Vital signs: trends in state suicide rates-United States, 1999-2016 and circumstances contributing to suicide-27 states, 2015. MMWR Morb Mortal Wkly Rep. 2018;67(22):617-624.
Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet (London, England). 2020;395(10222):450-462.
Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatr. 2018;5(2):175-186.
Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatr. 2006;163(4):716-723.
Septier M, Stordeur C, Zhang J, Delorme R, Cortese S. Association between suicidal spectrum behaviors and attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2019;103:109-118.
Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatr. 2018;5(9):727-738.
Klampfl K, Quattlander A, Burger R, Pfuhlmann B, Warnke A, Gerlach M. Case report: intoxication with high dose of long-acting methylphenidate (Concerta([R])) in a suicidal 14-year-old girl. Atten Deficit Hyperact Disord. 2010;2(4):221-224.
Paxton GA, Cranswick NE. Acute suicidality after commencing atomoxetine. J Paediatr Child Health. 2008;44(10):596-598.
Markx S, Kahn DA. An 18-year-old woman with new-onset suicidal ideation while being treated with atomoxetine. J Psychiatr Pract. 2008;14(1):62-66.
Chen Q, Sjolander A, Runeson B, D'Onofrio BM, Lichtenstein P, Larsson H. Drug treatment for attention-deficit_hyperactivity disorder and suicidal behaviour_ register based study. BMJ. 2014;348:g3769.
Davies M, Coughtrie A, Layton D, Shakir SA. Use of atomoxetine and suicidal ideation in children and adolescents results of an observational cohort study within general practice in England. Eur Psychiatr. 2017;39:11-16.
Man KKC, Coghill D, Chan EW, et al. Association of Risk of suicide attempts with methylphenidate treatment. JAMA Psychiatr. 2017;74(10):1048-1055.
Huang KL, Wei HT, Hsu JW, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder_ a nationwide longitudinal study. Br J Psychiatr. 2018;212(4):234-238.
Liang SH, Yang YH, Kuo TY, et al. Suicide risk reduction in youths with attention-deficit_hyperactivity disorder prescribed methylphenidate_ a Taiwan nationwide population-based cohort study. Res Dev Disabil. 2018;72:96-105.
Chang Z, Quinn PD, O'Reilly L, et al. Medication for attention-Deficit_Hyperactivity disorder and risk for suicide attempts. Biol Psychiatr. 2019. https://dor.org/10.1016/j.biopsych.2019.12.003.
Siffel C, DerSarkissian M, Kponee-Shovein K, et al. Suicidal ideation and attempts in The United States of America among stimulant-treated, non-stimulant-treated, and untreated patients with a diagnosis of attention-deficit/hyperactivity disorder. J Affect Disord. 2020;266:109-119.
Raman SR, Man KKC, Bahmanyar S, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatr. 2018;5(10):824-835.
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
Higgins. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration. 2014. Available from www.cochrane-handbook.org. December 6, 2014.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006;333(7568):597-600.
Taciak PP, Lysenko N, Mazurek AP. Drugs which influence serotonin transporter and serotonergic receptors: pharmacological and clinical properties in the treatment of depression. Pharmacol Rep. 2018;70(1):37-46.
Sharma T, Guski LS, Freund N, Gotzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ. 2016;352:i65.
Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatr. 2008;47(2):209-218.
Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol. 2014;24(8):426-434.
Bushe CJ, Savill NC. Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials. Child Adolesc Psychiatr Ment Health. 2013;7:19.
Braaten EB, Ward AK, Forchelli G, et al. Characteristics of child psychiatric outpatients with slow processing speed and potential mechanisms of academic impact. Eur Child Adolesc Psychiatr. 2020. https://doi.org/10.1007/s00787-019-01455-w.
Russell AE, Ford T, Russell G. Socioeconomic associations with ADHD: findings from a mediation analysis. PloS One. 2015;10(6):e0128248.
Mochrie KD, Whited MC, Cellucci T, Freeman T, Corson AT. ADHD, depression, and substance abuse risk among beginning college students. J Am Coll Health. 2020;68(1):6-10.
DuPaul GJ, Morgan PL, Farkas G, Hillemeier MM, Maczuga S. Eight-year latent class trajectories of academic and social functioning in children with attention-deficit/hyperactivity disorder. J Abnorm Child Psychol. 2018;46(5):979-992.
Gazer-Snitovsky M, Brand-Gothelf A, Dubnov-Raz G, Weizman A, Gothelf D. High familial correlation in methylphenidate response and side effect profile. J Atten Disord. 2019;23(2):135-139.
Clemow DB, Bushe CJ. Atomoxetine in patients with ADHD: a clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. J Psychopharmacol. 2015;29(12):1221-1230.
Wong ICK, Banaschewski T, Buitelaar J, et al. Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. Lancet Psychiatr. 2019;6(6):528-537.
Linden S, Bussing R, Kubilis P, et al. Risk of suicidal events with Atomoxetine compared to stimulant Treatment_ a cohort study. Pediatrics. 2016;137(5):e20153199.